$1,318.00
This Market Spotlight report covers the Overactive Bladder market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Overactive Bladder market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Lifestyle modifications and control techniques
8 Medical and surgical treatment
9 Products and devices
10 EPIDEMIOLOGY
13 MARKETED DRUGS
17 PIPELINE DRUGS
21 KEY UPCOMING EVENTS
22 KEY REGULATORY EVENTS
22 UK Looks To Switch Overactive Bladder Treatment
23 PROBABILITY OF SUCCESS
24 LICENSING AND ASSET ACQUISITION DEALS
24 Pierre Fabre Bags Rights To Overactive Bladder Drug
24 Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug
25 REVENUE OPPORTUNITY
27 CLINICAL TRIAL LANDSCAPE
28 Sponsors by status
29 Sponsors by phase
31 BIBLIOGRAPHY
32 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of overactive bladder, 2019–28
17 Figure 2: Overview of pipeline drugs for overactive bladder in the US
17 Figure 3: Pipeline drugs for overactive bladder, by company
17 Figure 4: Pipeline drugs for overactive bladder, by drug type
18 Figure 5: Pipeline drugs for overactive bladder, by classification
21 Figure 6: Key upcoming events in overactive bladder
23 Figure 7: Probability of success in the urology-other pipeline
27 Figure 8: Clinical trials in overactive bladder
27 Figure 9: Top 10 drugs for clinical trials in overactive bladder
28 Figure 10: Top 10 companies for clinical trials in overactive bladder
28 Figure 11: Trial locations in overactive bladder
29 Figure 12: Overactive bladder trials status
30 Figure 13: Overactive bladder trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of overactive bladder, 2019–28
14 Table 2: Marketed drugs for overactive bladder
19 Table 3: Pipeline drugs for overactive bladder in the US
25 Table 4: Historical global sales, by drug ($m), 2017–21
26 Table 5: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!